Interactive Video Gaming Device Could Aid MS Patients
|
By LabMedica International staff writers Posted on 23 Aug 2016 |

Image: Using Kinect motion-capture camera may improve evaluation of gait pathology in multiple sclerosis patients by increasing objectivity in diagnosis and treatment monitoring (Photo courtesy of the Montreal Neurological Institute & Hospital and McGill University).
A commonly used 3D depth-sensing camera could become a low-cost means of monitoring treatment effectiveness for walking difficulties of patients with gait-impairing diseases such as multiple sclerosis (MS).
The Microsoft “Kinect” motion-detection camera can be hooked up to an Xbox gaming console or a Windows computer for interactive video activities such as tennis and dancing. A team of researchers led by McGill University (Montreal, Quebec, Canada) postdoctoral fellow Farnood Gholami, supervised by Prof. Jozsef Kövecses, collaborated with Daria Trojan, physiatrist at the Montreal Neurological Institute and Hospital, to test whether the Kinect could detect the differences in gait of MS patients compared to healthy individuals. The tool could be useful “to assess treatment effects of certain interventions such as rehabilitation or medication, and to document MS disease progression as reflected by gait deterioration. It may also be useful as a measure in clinical trials,” said Trojan. Additional collaboration was with Behnood Gholami at AreteX Systems Inc. (Hoboken, NJ, USA) and Wassim M. Haddad at Georgia Institute of Technology, (Atlanta, GA, USA).
In current clinical practice, the walking movement of MS patients is usually assessed by their doctors using subjective evaluations that may distort results such that different clinicians may give different evaluations for the same patient. Using computer algorithms that quantify patient walking patterns detected by a camera can reduce potential for human error.
Using Kinect, Dr. Gholami captured the movement of 10 MS patients and 10 members of an age-and-sex-matched control group. The MS patients had previously been assessed for gait abnormalities using the traditional clinician method. Using the data, the team then developed computer algorithms that quantified gait characteristics of MS patients and healthy people. They found that gait characteristics measured with the Kinect camera and analyzed with the developed algorithms were reproducible when assessed at one visit and were different between MS patients and the healthy individuals. Moreover, the gait characteristics of MS patients obtained by the algorithm were correlated with clinical measures of gait. In addition, the algorithms could mathematically define the characteristics of gait in MS patients at different severity levels, accurately determining the level of gait abnormality.
Dr. Gholami became interested in using motion-capture technology for clinical purposes as a PhD student, but the equipment he was using at the time was very expensive, difficult to use, and non-portable, making widespread clinical use prohibitive. Kinect is an inexpensive tool that appears to be accurate enough to do the job. “This tool may help the clinician provide a better diagnosis of gait pathology, and may be used to observe if a prescribed medication has been effective on the gait of the patient or not,” he said, “Our developed framework can likely be used for other diseases causing gait abnormalities as well, for instance Parkinson’s disease.” The next step is to conduct a study with a larger group of MS patients, including evaluation in a gait laboratory, using a newer version of the Kinect device to improve accuracy.
The study, by Gholami F et al, was published July 21, 2016, in the IEEE Journal of Biomedical and Health Informatics.
Related Links:
McGill University
The Microsoft “Kinect” motion-detection camera can be hooked up to an Xbox gaming console or a Windows computer for interactive video activities such as tennis and dancing. A team of researchers led by McGill University (Montreal, Quebec, Canada) postdoctoral fellow Farnood Gholami, supervised by Prof. Jozsef Kövecses, collaborated with Daria Trojan, physiatrist at the Montreal Neurological Institute and Hospital, to test whether the Kinect could detect the differences in gait of MS patients compared to healthy individuals. The tool could be useful “to assess treatment effects of certain interventions such as rehabilitation or medication, and to document MS disease progression as reflected by gait deterioration. It may also be useful as a measure in clinical trials,” said Trojan. Additional collaboration was with Behnood Gholami at AreteX Systems Inc. (Hoboken, NJ, USA) and Wassim M. Haddad at Georgia Institute of Technology, (Atlanta, GA, USA).
In current clinical practice, the walking movement of MS patients is usually assessed by their doctors using subjective evaluations that may distort results such that different clinicians may give different evaluations for the same patient. Using computer algorithms that quantify patient walking patterns detected by a camera can reduce potential for human error.
Using Kinect, Dr. Gholami captured the movement of 10 MS patients and 10 members of an age-and-sex-matched control group. The MS patients had previously been assessed for gait abnormalities using the traditional clinician method. Using the data, the team then developed computer algorithms that quantified gait characteristics of MS patients and healthy people. They found that gait characteristics measured with the Kinect camera and analyzed with the developed algorithms were reproducible when assessed at one visit and were different between MS patients and the healthy individuals. Moreover, the gait characteristics of MS patients obtained by the algorithm were correlated with clinical measures of gait. In addition, the algorithms could mathematically define the characteristics of gait in MS patients at different severity levels, accurately determining the level of gait abnormality.
Dr. Gholami became interested in using motion-capture technology for clinical purposes as a PhD student, but the equipment he was using at the time was very expensive, difficult to use, and non-portable, making widespread clinical use prohibitive. Kinect is an inexpensive tool that appears to be accurate enough to do the job. “This tool may help the clinician provide a better diagnosis of gait pathology, and may be used to observe if a prescribed medication has been effective on the gait of the patient or not,” he said, “Our developed framework can likely be used for other diseases causing gait abnormalities as well, for instance Parkinson’s disease.” The next step is to conduct a study with a larger group of MS patients, including evaluation in a gait laboratory, using a newer version of the Kinect device to improve accuracy.
The study, by Gholami F et al, was published July 21, 2016, in the IEEE Journal of Biomedical and Health Informatics.
Related Links:
McGill University
Latest Technology News
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
Primary central nervous system lymphoma (PCNSL) is typically diagnosed through surgical biopsy, which remains the gold standard but carries substantial risk. Operability depends heavily on tumor location,... Read more
New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, marked by poor survival rates and limited treatment options, especially in patients who do not respond to standard therapies.... Read moreHematology
view channel
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channelAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read morePathology
view channel
AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
Accurately identifying genetic mutations is central to cancer diagnostics and genomic research, but current methods struggle with complex sequencing data and limited clinical samples. Tumor analysis often... Read more
Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
Transthyretin amyloidosis (ATTR) is a rare, progressive, and highly aggressive disease caused by the misfolding of a specific protein that accumulates as toxic amyloid filaments in multiple organs.... Read moreIndustry
view channel
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







